Innovative Science to Safeguard Every Newborn’s First Breath.
Transformative Respiratory Care for
Premature Infants
CanVeer Biopharma is dedicated to advancing life-changing therapeutics for premature infants.
Established with an urgent purpose to address one of neonatology’s most devastating and unmet
medical needs; Bronchopulmonary Dysplasia (BPD).
AlveoShield™ (Investigational New Drug) with
Potential to Prevent &
Reverse BPD
Drawing on decades of research in neonatal lung biology, and respiratory disease, Dr. Yeganeh
discovered a novel mechanism underlying Bronchopulmonary Dysplasia (BPD) pathogenesis. This scientific discovery led to the development of AlveoShield™, a first-in-class therapeutic candidate designed specifically to prevent and treat BPD in premature infants.
Recognizing the critical gap in treatments for BPD, a chronic lung condition affecting premature infants,
and the potential impact of AlveoShield™, the founders refocused CanVeer Biopharma to transition this
discovery into a clinically viable therapeutic and unlock its commercial value for global markets.
CanVeer Biopharma is built on a foundation of scientific excellence, business acumen, and a commitment to
ethical innovation.